ANZUP trials - bladder

ANZUP are currently running a number of bladder cancer trials. For more details information about these trials, go to the ANZUP bladder cancer trials web page: http://bit.ly/ANZUPbladder

Status: Open & recruiting

Location: Australia

Activated sites: 12

Patients recruited: 309

Patients required: Stage one: 130 / Stage two: 370

Non-muscle invasive bladder cancer is common and causes substantial suffering. It requires removal or irradiation of the bladder within five years in more than 30% of people with high-risk tumours, despite best current treatment.

Recent preliminary studies show promising results from adding mitomycin (MM), a chemotherapy drug, to current treatment with BCG (Bacillus Calmette-Guérin, a strain of modified bacteria which stimulates an immune response to early cancer cells).

This randomised trial will determine the effects of adding mitomycin on cure rates, survival, side effects and quality of life. This could potentially provide a simple and costeffective treatment for patients who suffer from this cancer.

This study is currently active and recruiting. Please speak with your doctor if this is of interest to you or someone you know.

ANZUP collaborates with the University of Sydney through the National Health and Medical Research Council Clinical Trials Centre (NHMRC CTC). This ANZUP investigator-initiated study is being funded by Cancer Australia and the National Health and Medical Research Council. We acknowledge Omegapharm and Merck Sharp & Dohme for providing the study drugs.

Current site locations for the BCG + MM trial are:

NSW •Concord Repatriation General Hospital •John Hunter Hospital •Northern Cancer Institute, St Leonards •Southside Cancer Care Centre •The Tweed Hospital •Westmead Hospital

VIC •The Alfred Hospital •Austin Hospital •Epworth HealthCare (Richmond) •Frankston Hospital •Royal Melbourne Hospital

WA •Fiona Stanley Hospital

PCR-MIB

Participation in cancer trials is voluntary & patients can withdraw from a study at any time

Status: Open & recruiting Location: Australia wide Activated sites: 6 Patients recruited: 24 • Patients required: 30

Opened in mid-2016, this trial is aimed at managing bladder cancer that has spread into the wall of the bladder. A combination of chemotherapy and radiotherapy is the current standard treatment. This study aims to assess if it is safe and effective to add an additional new drug called pembrolizumab to the standard therapy of chemotherapy and radiation therapy.

Pembrolizumab is a new treatment that “takes the brakes off” the immune system, allowing it to attack cancers more effectively. Studies of pembrolizumab in widespread bladder cancer have shown benefit, with cancer shrinkage observed in about two thirds of people, and in some cases long periods of disease control. At present, pembrolizumab, is approved for use in Australia for the treatment of advanced melanoma in adults.

This study is currently active and recruiting. Please speak with your doctor if this is of interest to you or someone you know.

We thank and acknowledge MSD for their funding and product support.

If a clinical trial proves that a treatment is more effective than existing options, it may become the new standard of care for patients in the future.

Current site locations for the PCR-MIB ANZUP clinical trial:

NSW

• Chris O’Brien Lifehouse

• Liverpool Hospital

• Prince of Wales Hospital

• Royal North Shore Hospital

VIC

• Austin Hospital

WA

• Sir Charles Gairdner Hospital